Full Press Release Details
Mainz Biomed Reports Results of 2024 Annual
BERKELEY, US - MAINZ, Germany - May 31, 2024 -
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, , held its annual
general meeting ("Annual General Meeting") on Friday, May 31, 2024 in Amsterdam, The Netherlands. Holders of 2,431,947 ordinary
shares, representing approximately 10.9% of our outstanding shares on May 3, 2024, the record date for the Annual General Meeting, were
present at such meeting, which constituted a quorum under Dutch law. Each of the matters presented at the Annual General Meeting received
the requisite shareholder approval as set below:
| Proposal | For | Against | Abstain | |||||||||||
| 1. | Adoption of the statutory annual accounts for the financial year ended 31 December 2023 | 2,400,449 | 22,528 | 8,970 | ||||||||||
| 2. | Discharge from liability of the directors for their management and supervision during the financial year ended 31 December 2023 | 2,187,602 | 198,949 | 45,396 | ||||||||||
| 3. | Amendment of the articles of association and authorization of CMS to have the deed of amendment of articles of association executed | 2,344,801 | 32,166 | 54,980 | ||||||||||
| 4. | Extension of the authorization of the board to acquire ordinary shares or depositary receipts thereof | 2,229,837 | 169,972 | 32,138 | ||||||||||
| 5. | Extension of the authorization of the board to acquire preferred shares or depositary receipts thereof | 2,103,796 | 296,901 | 31,250 | ||||||||||
| 6. | Reappointment of Mr. G. Baechler as executive director | 2,368,376 | 31,476 | 32,095 | ||||||||||
| 7. | Reappointment of Mr. H.J. Hekland as non-executive director | 2,371,381 | 31,481 | 29,085 | ||||||||||
| 8. | Reappointment of Mr. G.J. Tibbitts as non-executive director | 2,378,154 | 46,443 | 7,350 | ||||||||||
| 9. | Reappointment of Dr. H. Dreismann as non-executive director | 2,372,910 | 29,939 | 29,098 | ||||||||||
| 10. | Assignment of Kreston Lentink Audit B.V. as Dutch auditor and authorization of the board to assign a US auditor at its discretion for the financial year ending 31 December 2024 | 2,378,052 | 25,907 | 27,988 |
No other matters were voted upon at the Annual General Meeting.
In addition to announcing the results of its Annual General Meeting,
Mainz also addresses a recent notification from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq ")
regarding the company's compliance with the minimum bid price requirement. Nasdaq has informed Mainz that it is currently not in
compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the company's ordinary shares was below the minimum
of US$1.00 per share for 30 consecutive trading days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), Mainz Biomed N.V. has been granted
a compliance period of 180 calendar days to regain compliance with Nasdaq's minimum bid price requirement. To regain compliance,
the closing bid price of the ordinary shares must be at least $1.00 per share for a minimum of 10 consecutive trading days prior to November
25, 2024 and the Company must otherwise satisfy The Nasdaq Capital Market's requirements for listing. If the company does not regain
compliance by November 25, 2024, the company may be eligible for an additional 180 calendar day compliance period. If the company does
not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide
notice that the company's ordinary shares will be subject to delisting. The company would then be entitled to appeal Nasdaq's
determination to a Nasdaq Listing Qualifications Panel and request a hearing.
Please follow us to stay up to date:
X (Previously Twitter)
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular
genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert , an accurate,
non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based
(PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert is currently marketed across Europe. The Company
is planning to run a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes
PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com.
Anne Hennecke/Caroline Bergmann
For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are "forward-looking
statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect",
"estimate", "plan", "outlook", and "project" and other similar expressions that predict
or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current
analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying
on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations
or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking
statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the
effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein,
as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and
Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact
the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form
20-F filed on April 9, 2024. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward-looking
statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the
date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral,
that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.